Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 28 Mar 23 EFFECT Notice of effectiveness
- 24 Mar 23 POS AM Prospectus update (post-effective amendment)
- 7 Jun 21 EFFECT Notice of effectiveness
- 18 May 21 POS AM Prospectus update (post-effective amendment)
- 12 Feb 21 424B3 Prospectus supplement
- 12 Feb 21 EFFECT Notice of effectiveness
- 8 Feb 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
16 Oct 20 S-4 Registration of securities issued in business combination transactions
VYNT similar filings
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the use in this Registration Statement on Form S-4 of Cancer Genetics, Inc. & Subsidiaries of our report dated April 15, 2019, relating to the consolidated financial statements of Cancer Genetics, Inc. & Subsidiaries as of December 31, 2018 and for the year then ended, before the effects of the adjustments for discontinued operations and a reverse stock-split, appearing in the Proxy Statement/Prospectus, which is part of this Registration Statement.
We also consent to the reference to our firm under the heading “Experts” in such Proxy Statement/Prospectus.
/s/ RSM US LLP
New York, NY
October 16, 2020